The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
about
Recognizing Potential Buprenorphine Medication Misuse: Product Packaging Does Not Degrade With Laundering.Two cases of intranasal naloxone self-administration in opioid overdose.The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.Polydrug abuse: a review of opioid and benzodiazepine combination useIntranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusersA response to the opioid overdose epidemic: naloxone nasal sprayDetermination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.Clinician beliefs and attitudes about buprenorphine/naloxone diversionStroke from Vasospasm due to Marijuana Use: Can Cannabis Synergistically with Other Medications Trigger Cerebral Vasospasm?Intranasal oxycodone self-administration in non-dependent opioid abusers.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.Reducing the harm of opioid overdose with the safe use of naloxone : a pharmacologic review.International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.Oxytocin under opioid antagonism leads to supralinear enhancement of social attention.Update on pharmacotherapy for treatment of opioid use disorder.Buprenorphine treatment for narcotic addiction: not without risks.Acute hepatitis and renal failure related to intranasal buprenorphine misuse: case report and analysis of cases reported to the French network for drug monitoring.Pharmacokinetics of a new, nasal formulation of naloxone.
P2860
Q30300304-42380315-8C9D-4C01-820C-C3E6ED4F91A6Q33606282-0A493A91-41A8-41C2-ADFA-8D6A60C5C335Q33889324-FCD47D88-060A-4DD6-9E26-280417CCE81DQ34253036-3119F888-6A75-404B-B39F-3413A3034B58Q34952233-8F0705A4-D027-4186-97EB-8A8A5A346E4BQ35009760-43755AB7-50FE-4957-9AAF-25031DB58C0CQ36253355-3E1F5ECB-63BB-4F9D-9FEA-A44BACECEF9CQ36266246-837365DC-490D-4486-8684-D157A464A46EQ36803326-2CF00E9F-03D9-43F3-BD5E-AA9AC9AF7935Q36890018-A4FDE5FF-B53A-4CD2-A99D-579B2160B9D9Q37003866-7C71190E-B16B-446B-A394-C846FCD6CA5EQ37241381-217B4103-F01B-4FFA-B112-2FC1BF028D67Q37385795-FA352C18-DEF1-4807-A485-5DC47189F652Q37391604-6CB6A3EF-451C-4121-9934-3F0CB32EC2A0Q38093852-5A1ECEA7-7103-460C-A226-F9B6E485040BQ38374886-CCA22949-29EA-4C46-8E35-374B2B544C65Q38379235-6A93F2FA-47A2-45B9-971A-6DE30B7F9CD9Q38417339-478E7D81-03C3-45A6-B682-D015576B40DAQ38734821-801BCF05-1277-4B72-91ED-88E20C8C9220Q38810226-6245635B-3302-42BB-9FD4-987A4EE878C1Q38979423-E60A3198-9ACF-46F5-8B6F-FEBE93071990Q40283005-457E8E6F-9F16-42C7-A6E6-E2B18413A361Q42254138-69F73DDF-ECD7-4A55-8643-71142F038FF5Q50920381-8B2673FF-8D4B-49F6-A9DB-08257A53A932
P2860
The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The pharmacodynamic and pharma ...... one tablets in opioid abusers.
@en
The pharmacodynamic and pharma ...... one tablets in opioid abusers.
@nl
type
label
The pharmacodynamic and pharma ...... one tablets in opioid abusers.
@en
The pharmacodynamic and pharma ...... one tablets in opioid abusers.
@nl
prefLabel
The pharmacodynamic and pharma ...... one tablets in opioid abusers.
@en
The pharmacodynamic and pharma ...... one tablets in opioid abusers.
@nl
P2093
P2860
P1433
P1476
The pharmacodynamic and pharma ...... one tablets in opioid abusers.
@en
P2093
David E Moody
Lisa S Middleton
Michelle R Lofwall
Paul A Nuzzo
Sharon L Walsh
P2860
P304
P356
10.1111/J.1360-0443.2011.03424.X
P407
P577
2011-05-03T00:00:00Z